RGEN
Signal
Leaning Bullish1
Price
1
Move+0.86%Quiet session
Volume
1
Volume1.4× avgNormal activity
Technical
1
RSIRSI 50Momentum positive
PRICE
Prev Close
117.20
Open
116.05
Day Range116.05 – 120.18
116.05
120.18
52W Range109.50 – 175.77
109.50
175.77
13% of range
VOLUME & SIZE
Avg Volume
942.9K
FUNDAMENTALS
P/E Ratio
137.4x
Premium valuation
EPS (TTM)
Div Yield
No dividend
Beta
1.38
Market-like
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +16% YoY · 51% gross margin
Valuation
EXPENSIVE
P/E 137x vs ~20x sector
Health
STRONG
CR 8.4 · FCF $1.62/sh
Bullish
Key MetricsTTM
Market Cap$6.67B
Revenue TTM$738.26M
Net Income TTM$48.89M
Free Cash Flow$91.34M
Gross Margin50.9%
Net Margin6.6%
Operating Margin7.6%
Return on Equity2.4%
Return on Assets1.7%
Debt / Equity0.33
Current Ratio8.37
EPS TTM$0.87

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
46/100
Liquidity
8.37Strong
Leverage
0.33Strong
Coverage
1.2xConcern
ROE
2.4%Concern
ROIC
1.5%Concern
Cash
$566MStrong
ANALYST COVERAGE23 analysts
BUY
+35.4%upside to target
L $145.00
Med $160.00consensus
H $200.00
Strong Buy
14%
Buy
1983%
Hold
313%
20 Buy (87%)3 Hold (13%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 4 signals bullish
10/10
Technicals
RSI RangeRSI 50 — Bullish momentum
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 8.37 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings Report · Before OpenMay 6, 2026
Tomorrow
DEx-Dividend DateAug 3, 2026
In 90 days
PDividend PaymentAug 20, 2026
In 107 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendDeath Cross · 50D trails 200D by 2.0%

-12.9% vs SMA 50 · -14.7% vs SMA 200

Momentum

RSI50.1
Neutral territory
MACD-6.26
Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$175.8+48.7%
EMA 200
$135.2+14.3%
EMA 50
$131.5+11.2%
Current
$118.2
52W Low
$109.5-7.4%
52-Week RangeNear 52-week low
$109.513th %ile$175.8
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 15 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$733.1M
$729.9M$734.8M
$1.66
±1%
High12
FY2026(current)
$827.3M
$821.1M$833.9M
+12.8%$1.97+18.2%
±1%
High15
FY2027
$948.5M
$938.1M$959.7M
+14.7%$2.55+29.7%
±16%
High14
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryRGEN
Last 8Q
+7.1%avg beat
Beat 5 of 8 quartersMissed 2 Estimates rising
-3%
Q2'24
Q3'24
+28%
Q4'24
+7%
Q1'25
+11%
Q2'25
-8%
Q3'25
+10%
Q4'25
+11%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →
No recent activity
Evercore ISIOutperform
Sep 22
UPGRADE
BMO CapitalOutperform
Jun 26
UPGRADE
Deutsche BankHold → Buy
Jun 26
UPGRADE
Piper SandlerUnderweight
Jul 6
DOWNGRADE
RBC CapitalSector Perform → Outperform
Jul 6
UPGRADE
UBSNeutral
Jul 6
DOWNGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $536K sold · 30d window
Loeillot OlivierCEO
$536K
Apr 21
SELL
Dawes Karen ADir
$44K
Dec 17
SELL
Loeillot OlivierCEO
$1.2M
Nov 25
SELL
Bylund JamesCOO
$331K
Nov 18
SELL
Hunt AnthonyDir
$269K
Nov 13
SELL
Hunt AnthonyDir
$320K
Nov 13
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
WASATCH ADVISORS LP
1.2M
2
Conestoga Capital Advisors, LLC
1.1M
3
CONGRESS ASSET MANAGEMENT CO /MA
798K
4
Stephens Investment Management Group LLC
756K
5
THRIVENT FINANCIAL FOR LUTHERANS
425K
6
Artemis Investment Management LLP
422K
7
RIVERBRIDGE PARTNERS LLC
258K
8
FIFTH THIRD BANCORP
161K
News & Activity

RGEN News

20 articles · 4h ago

About

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Anthony Hunt
Olivier LoeillotPresident, Chief Executive Officer & Director
Neil WhitfieldSenior Vice President of Sales
Jacob K. JohnsonVice President of Investor Relations